Explore how the FDA monitors generic drug safety after approval using post-market surveillance, DQRS data, and MedWatch reports to catch manufacturing defects and therapeutic inequivalence.
Continue Reading
The FDA Sentinel Initiative uses big data from millions of patient records to detect hidden drug risks in real time. Unlike old reporting systems, it tracks actual usage rates and finds dangers before they spread.
Continue Reading
